Nuzhat Tam-Zaman1, Yun K Tam, Soheir Tawfik, Hugh Wiltshire. 1. Pharmacokinetics/Pharmacodynamics Department, Kinetana Group Inc., 108 Advanced Technology Center, Edmonton, Alberta, Canada. ntzaman@kinetana.com
Abstract
PURPOSE: To study the effect of dose and food on the bioavailability of saquinavir in dogs. METHODS: A Youden Square block design was used for six female mongrel dogs (20-24 kg) who received six saquinavir treatments. The six randomized treatments were 1 mg/kg intravenous infusion over 30 min; 200, 400, 600, and 800 mg of saquinavir in the form of 200-mg capsules given orally with food; and 400 mg of saquinavir given orally after an overnight fast. A 200-mg 14C-saquinavir capsule was used to replace one of the 200-mg unlabeled saquinavir capsules in the 200- and 800-mg oral study. RESULTS: Absorption of saquinavir from the gut was variable. (F(A): 49-95%). The 14C-saquinavir study shows that the total radioactivity absorbed from the gut was insignificantly different from that of unlabeled saquinavir, suggesting first-pass gut metabolism was unimportant. The bioavailability of saquinavir under fasting condition was significantly lower (8.41 +/- 4.7% vs. 20.3 +/- 2.6%, p < 0.05). Saquinavir underwent significant first-pass liver metabolism because hepatic clearance values (22 to 30 ml min(-1) kg(-1)) approached that of liver blood flow. CONCLUSIONS: Incomplete gut absorption and extensive first-pass liver metabolism are the causes for low bioavailability of saquinavir in dogs. Absorption was further reduced under fasted conditions.
PURPOSE: To study the effect of dose and food on the bioavailability of saquinavir in dogs. METHODS: A Youden Square block design was used for six female mongrel dogs (20-24 kg) who received six saquinavir treatments. The six randomized treatments were 1 mg/kg intravenous infusion over 30 min; 200, 400, 600, and 800 mg of saquinavir in the form of 200-mg capsules given orally with food; and 400 mg of saquinavir given orally after an overnight fast. A 200-mg 14C-saquinavir capsule was used to replace one of the 200-mg unlabeled saquinavir capsules in the 200- and 800-mg oral study. RESULTS: Absorption of saquinavir from the gut was variable. (F(A): 49-95%). The 14C-saquinavir study shows that the total radioactivity absorbed from the gut was insignificantly different from that of unlabeled saquinavir, suggesting first-pass gut metabolism was unimportant. The bioavailability of saquinavir under fasting condition was significantly lower (8.41 +/- 4.7% vs. 20.3 +/- 2.6%, p < 0.05). Saquinavir underwent significant first-pass liver metabolism because hepatic clearance values (22 to 30 ml min(-1) kg(-1)) approached that of liver blood flow. CONCLUSIONS: Incomplete gut absorption and extensive first-pass liver metabolism are the causes for low bioavailability of saquinavir in dogs. Absorption was further reduced under fasted conditions.
Authors: Marta Boffito; Pierluigi Carriero; Laura Trentini; Riccardo Raiteri; Stefano Bonora; Alessandro Sinicco; Helen E Reynolds; Patrick G Hoggard; David J Back; Giovanni Di Perri Journal: J Antimicrob Chemother Date: 2002-12 Impact factor: 5.790
Authors: C B Washington; H R Wiltshire; M Man; T Moy; S R Harris; E Worth; P Weigl; Z Liang; D Hall; L Marriott; T F Blaschke Journal: Drug Metab Dispos Date: 2000-09 Impact factor: 3.922
Authors: C Merry; M G Barry; F Mulcahy; M Ryan; J Heavey; J F Tjia; S E Gibbons; A M Breckenridge; D J Back Journal: AIDS Date: 1997-03-15 Impact factor: 4.177
Authors: V S Kitchen; C Skinner; K Ariyoshi; E A Lane; I B Duncan; J Burckhardt; H U Burger; K Bragman; A J Pinching; J N Weber Journal: Lancet Date: 1995-04-15 Impact factor: 79.321